Cynata Therapeutics Email Format

Biotechnology ResearchVictoria, Australia11-50 Employees

Cynata Therapeutics is an Australian clinical‑stage biotechnology company focused on regenerative medicine, pursuing therapies built on its Cymerus approach. Cymerus uses induced pluripotent stem cells and a mesenchymoangioblast precursor to produce mesenchymal stem cell products at commercial scale, reducing dependence on cells from multiple donors. The company is based in Cremorne, Victoria, and aims to translate stem cell science into scalable, clinically developable therapies.

Its lead product candidate, CYP-001, has met clinical endpoints in a Phase 1 trial for steroid-resistant acute graft-versus-host disease, with positive safety and efficacy signals reported. Ongoing programs include a Phase 3 study in osteoarthritis and a Phase 2 trial addressing severe complications from COVID-19, with additional development planned in other indications through partnerships such as licensing arrangements for GvHD with Fujifilm. Cynata describes itself as a small to mid-sized Australian biotechnology company operating in the regenerative medicine space.

Sign up for free to view info

Company overview Employee directory